Thu May 20 2021
Early start of anakinra treatment guided by suPAR provides 2.78 times better improvement of overall clinical status in patients with moderate and severe COVID-19 pneumonia
SAVE-MORE is a multicenter, double-blinded, randomised controlled trial in 594 hospitalised patients that specifically identifies those at risk of severe respiratory failure by the measurement of elevated suPAR, a plasma biomarker that reflects immune activation and has been previously associated with poor prognosis in a number of conditions.
The preprint is now published, and the results show that early, suPAR-guided use of anakinra in addition to the current standard of care in hospitalised patients with poor prognosis, as demonstrated by an elevated suPAR level (above 6 ng/ml), prevented either death or progression to severe respiratory failure, whilst increasing the number of patients who were discharged from hospital with no evidence of COVID-19 infection.
Summary of results
- Early start of anakinra treatment guided by suPAR provides 2.78 times better improvement of overall clinical status in patients with moderate and severe COVID-19 pneumonia
- 28-day mortality decreased (Hazard ratio: 0.45; P: 0.045)
- Anakinra-treated patients were distributed to lower strata of WHO-CPS by day 28 (adjusted odds ratio-OR 0.36; 95%CI 0.26-0.50; P<0.001)
- Anakinra protected from severe disease or death (6 or more points of WHO-CPS) (OR: 0.46; P: 0.01)
- Hospital stay was shorter
Early start of anakinra treatment guided by suPAR provides 2.78 times better improvement of overall clinical status in moderate and severe COVID-19 pneumonia.
The study is sponsored by the Hellenic Institute for the Study of Sepsis (HISS) in Greece and led by its President and Chairman, Professor Evangelos J. Giamarellos-Bourboulis. Giamarellos-Bourboulis is Professor of Internal Medicine and Infectious Diseases at the National and Kapodistrian University of Athens, President of the European Shock Society and Chairman of the European Sepsis Alliance.